Biomarker Clinical Phase Outsourcing Services

Global Biomarker Clinical Phase Outsourcing Services Market to Reach US$26.9 Billion by 2030

The global market for Biomarker Clinical Phase Outsourcing Services estimated at US$9.2 Billion in the year 2024, is expected to reach US$26.9 Billion by 2030, growing at a CAGR of 19.5% over the analysis period 2024-2030. Predictive Biomarkers, one of the segments analyzed in the report, is expected to record a 20.2% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Prognostic Biomarkers segment is estimated at 21.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 18.4% CAGR

The Biomarker Clinical Phase Outsourcing Services market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.1 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.8% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global Biomarker Clinical Phase Outsourcing Services Market - Key Trends & Drivers Summarized

Why Is the Demand for Biomarker Clinical Phase Outsourcing Services Rising?

The rapid expansion of precision medicine and targeted therapies has significantly increased the need for biomarker-based clinical trials, leading pharmaceutical and biotechnology companies to outsource key phases of biomarker development. Biomarker clinical phase outsourcing services encompass a wide range of functions, including biomarker validation, patient stratification, bioanalytical testing, and regulatory compliance support. As drug development processes become more complex and data-driven, outsourcing these critical phases to specialized contract research organizations (CROs) is becoming an essential strategy to streamline operations and accelerate time-to-market. Additionally, the growing prevalence of chronic diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions has fueled the need for biomarker-driven diagnostics and therapeutic solutions. Biomarkers play a crucial role in predicting disease progression, assessing treatment responses, and minimizing adverse effects, making them indispensable for modern clinical trials. As pharmaceutical companies strive to develop highly personalized treatment regimens, the demand for outsourced biomarker services is surging, allowing them to leverage the expertise, infrastructure, and regulatory proficiency of specialized CROs.

How Are Technological Advancements Transforming Biomarker Outsourcing Services?

Technological innovations are revolutionizing the biomarker outsourcing landscape, enabling faster, more accurate, and cost-effective clinical phase studies. Advances in genomics, proteomics, and metabolomics have led to the discovery of novel biomarkers, improving early disease detection and therapeutic monitoring. AI and machine learning are further enhancing biomarker data analysis, allowing researchers to identify meaningful patterns and correlations from vast datasets, optimizing patient selection, and improving trial success rates. Moreover, the integration of next-generation sequencing (NGS) and digital pathology in biomarker analysis is providing more precise insights into disease mechanisms. These technologies are improving the efficiency of companion diagnostics and enhancing the development of targeted therapies. Additionally, the use of liquid biopsy techniques is gaining traction in biomarker-based clinical trials, allowing for real-time monitoring of disease progression through minimally invasive procedures. As these technological advancements continue to shape biomarker development, outsourcing services are becoming increasingly sophisticated, offering more comprehensive and tailored solutions for pharmaceutical and biotech companies.

What Market Trends Are Driving the Growth of Biomarker Clinical Phase Outsourcing Services?

One of the most prominent trends shaping the biomarker outsourcing market is the increasing focus on personalized medicine. As healthcare shifts from a one-size-fits-all approach to more individualized treatment strategies, the need for biomarker-driven drug development has intensified. Pharmaceutical firms are leveraging biomarker outsourcing services to conduct specialized clinical trials that identify patient subgroups most likely to benefit from specific therapies, improving treatment outcomes and regulatory approval chances. Another key market trend is the rise of decentralized and virtual clinical trials. With advancements in digital health technologies and remote patient monitoring, biomarker research is expanding beyond traditional clinical settings. CROs are increasingly offering remote biomarker collection, AI-driven analytics, and cloud-based data management solutions, enhancing the efficiency and accessibility of outsourced clinical trial phases. Furthermore, regulatory agencies such as the FDA and EMA are promoting biomarker-driven drug approvals, further encouraging pharmaceutical companies to invest in outsourced biomarker validation and testing services.

What Are the Key Growth Drivers for the Biomarker Clinical Phase Outsourcing Services Market?

The growth in the Biomarker Clinical Phase Outsourcing Services market is driven by several factors, including the increasing complexity of clinical trials, rising demand for personalized medicine, and advancements in biomarker research technologies. The high costs and resource-intensive nature of biomarker development have made outsourcing an attractive option for pharmaceutical companies seeking to optimize their drug pipelines and reduce operational burdens. The globalization of clinical trials is also contributing to market expansion, as outsourcing enables pharmaceutical firms to conduct multi-regional biomarker studies while ensuring compliance with regulatory requirements. Additionally, the growing adoption of AI and big data analytics in biomarker research is streamlining data interpretation and improving clinical trial efficiencies. With continuous innovations in precision medicine and biomarker discovery, the market for outsourced biomarker clinical phase services is expected to witness exponential growth, positioning CROs as indispensable partners in the future of drug development and personalized healthcare.

SCOPE OF STUDY:

The report analyzes the Biomarker Clinical Phase Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Biomarker Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints); Therapeutic Area (Oncology Therapeutic Area, Neurology Therapeutic Area, Cardiology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

• Celerion
• Charles River Laboratories
• Clario
• Eurofins Scientific SE
• GenScript Biotech Corporation
• ICON Plc
• IQVIA
• Laboratory Corporation of America Holdings
• NorthEast BioAnalytical Laboratories LLC
• Parexel International Corporation
• Proteome Sciences
• Syneos Health

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.